Our latest press releases, media appearances and news commentary.
Medicines Discovery Catapult, the Centre for Drug Safety Sciences at the University of Liverpool and the NC3Rs combine forces.
CEO, Chris Molloy, responds to the findings and recommendations.
Mark Samuels, our Chief Business & Strategy Officer, was recently profiled in PharmaTimes.
CEO, Chris Molloy, has an article featured at Open Access Government.
Tissue Solutions and Medicines Discovery Catapult launch service to support UK companies and biobanks.
New drug discovery research to tackle the growing health epidemic of antimicrobial resistance will soon be underway.
UK pharma R&D productivity is at an all-time low, warns our CEO Chris Molloy.
Peter will be joining their board this year along with Emilio Diez Monedero and Severine Tamas-Lhoustau.
The Medicines Discovery Catapult and BioIndustry Association call on the R&D community to address five themes to help boost productivity.
Our Chief Executive Officer, Chris Molloy, explores how Medicines Discovery Catapult is supporting the community to realise the future of drug discovery.
See how we can help support you with your next drug discovery project.
Speak to us